RNA

Total RNA was prepared from cell line WM3456. WM3456 is a human metastatic melanoma cell line that displays a thin elongated, fibroblastic morphology. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation.  WM3456 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3456. WM3456 is a human metastatic melanoma cell line that displays a thin elongated, fibroblastic morphology. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation.  WM3456 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3482. WM3482 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3482 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3482. WM3482 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3482 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3482. WM3482 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3482 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3506. WM3506 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. WM3506 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3506. WM3506 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. WM3506 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3506. WM3506 is a human metastatic melanoma cell line that displays a mesenchymal morphology. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. WM3506 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3533. WM3533 is a human metastatic melanoma cell line that displays a fibroblastic morphology. This cell line was established from a lymph node metastases of a patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3533 cells produce xenograft tumors when injected into immunocompromised mice.